Bellevue Group Ag Esperion Therapeutics, Inc. Call Options Transaction History
Bellevue Group Ag
- $5.93 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ESPR
# of Institutions
208Shares Held
128MCall Options Held
1.67MPut Options Held
930K-
Wasatch Advisors Inc Salt Lake City, UT23.3MShares$56.3 Million0.19% of portfolio
-
Black Rock Inc. New York, NY14MShares$33.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13MShares$31.4 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$15.9 Million3.65% of portfolio
-
Geode Capital Management, LLC Boston, MA4.33MShares$10.4 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $160M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...